Neuromyelitis Optica Spectrum Disorder (NMOSD)
Oncology·MeSH: Neuromyelitis Optica
Prevalence
30.0 / 100K
2 drugs in development·2 companies·2 clinical trials
Drug Pipeline by Phase
Approved(2)
Compare drugs
Frequently asked questions
How many drugs are in development for Neuromyelitis Optica Spectrum Disorder (NMOSD)?
BioSniper tracks 2 drugs in development for Neuromyelitis Optica Spectrum Disorder (NMOSD) across 2 companies.
How many clinical trials target Neuromyelitis Optica Spectrum Disorder (NMOSD)?
There are 2 clinical trials targeting Neuromyelitis Optica Spectrum Disorder (NMOSD) tracked by BioSniper.
What is the prevalence of Neuromyelitis Optica Spectrum Disorder (NMOSD)?
The estimated prevalence of Neuromyelitis Optica Spectrum Disorder (NMOSD) is approximately 30.0 per 100,000 population.
Deep-dive into Neuromyelitis Optica Spectrum Disorder (NMOSD)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis